00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Revolution Medicine said its pancreatic cancer drug met all primary and secondary endpoints in
00:07a phase three trial and doubled the length of survival compared with chemotherapy,
00:12according to CNBC. Patients who took the daily pill lived 13.2 months versus 6.7 months for
00:19chemotherapy, reducing the risk of death by 60%. CEO. Mark Goldsmith called the results
00:27unprecedented and said the company will seek food and drug administration approval
00:31using a priority review voucher. The drug targets RAS mutations found in about 90% of pancreatic
00:37cancer cases. Doctors said the results are transformational after prior studies showed
00:42only modest gains. For all things money, visit Benzinga.com.
Comments